This article is an erratum on:
Type 1 regulatory T cell-mediated tolerance in health and disease
An Erratum on
Type 1 regulatory T cell-mediated tolerance in health and disease
By Freeborn RA, Strubbe S and Roncarolo MG (2022) Front. Immunol. 13:1032575. doi: 10.3389/fimmu.2022.1032575
Due to a production error, there was a mistake in Table 1 as published. Some of the citations in Table 1 did not link to the correct references in the reference list. The corrected Table 1 appears below. The publisher apologizes for this mistake.
TABLE 1
Table 1 Overview of the role of Tr1 and IL-10-producing CD4+ T cells in AIDs and IBD.
The original version of this article has been updated.
References
1. Bluestone JA, Anderson M. Tolerance in the age of immunotherapy. New Engl J Med (2020) 383:1156–66. doi: 10.1056/nejmra1911109
2. Roncarolo MG, Yssel H, Touraine J-L, Bacchetta R, Gebuhrer L, de Vries JE, et al. Antigen recognition by MHC-incompatible cells of a human mismatched chimera. J Exp Med (1988) 168:2139–51. doi: 10.1084/jem.168.6.2139
3. Bacchetta R, Bigler M, Touraine J-L, Parkman R, Tovo P-A, Abrams J, et al. High levels of interleukin 10 production In vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med (1994) 179:493–502. doi: 10.1084/jem.179.2.493
4. Groux H, O’Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature (1997) 389:737–42. doi: 10.1038/39614
5. Bacchetta R, Sartirana C, Levings MK, Bordignon C, Narula S, Roncarolo MG. Growth and expansion of human T regulatory type 1 cells are independent from TCR activation but require exogenous cytokines. Eur J Immunol (2002) 32:2237–45. doi: 10.1002/1521-4141(200208)32:8<2237::AID-IMMU2237>3.0.CO;2-2
6. de Waal-Malefyt R, Haanen J, Spits H, Roncarolo M-G, te Velde A, Figdor C, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med (1991) 174:915–24. doi: 10.1084/jem.174.4.915
7. Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol (1993) 151:1224–34.
8. Willems F, Marchant A, Delville J-P, Gerard C, Delvaux A, Velu T, et al. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocyt es. Eur J Immunol (1994) 24:1007–9. doi: 10.1002/eji.1830240435
9. Chang C-H, Furue M, Tamaki K. B7-1 expression of langerhans cells is up-regulated by proinflammatory cytokines, and is down-regulated by interferon-y or by int erleukin-10. Eur J Immunol (1995) 25:394–8. doi: 10.1002/eji.1830250213
10. Tree TIM, Lawson J, Edwards H, Skowera A, Arif S, Roep BO, et al. Naturally arising human CD4 T-cells that recognize islet autoantigens and secrete interleukin-10 regulate proinflammatory T-cell responses via linked suppression. Diabetes (2010) 59:1451–60. doi: 10.2337/db09-0503
11. Gruarin P, Maglie S, de Simone M, Häringer B, Vasco C, Ranzani V, et al. Eomesodermin controls a unique differentiation program in human IL-10 and IFN-γ coproducing regulatory T cells. Eur J Immunol (2019) 49:96–111. doi: 10.1002/eji.201847722
12. Magnani CF, Alberigo G, Bacchetta R, Serafini G, Andreani M, Roncarolo MG, et al. Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cells. Eur J Immunol (2011) 41:1652–62. doi: 10.1002/eji.201041120
13. Meiler F, Zumkehr J, Klunker S, Rückert B, Akdis CA, Akdis M. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med (2008) 205:2887–98. doi: 10.1084/jem.20080193
14. Chen PP, Cepika A, Agarwal-hashmi R, Saini G, Uyeda MJ, Louis DM, et al. Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients. Sci Transl Med (2021) 13:eabf5264. doi: 10.1126/scitranslmed.abf5264
15. Sumitomo S, Nakachi S, Okamura T, Tsuchida Y, Kato R, Shoda H, et al. Identification of tonsillar CD4+CD25–LAG3+ T cells as naturally occurring IL-10-producing regulatory T cells in human lymphoid tissue. J Autoimmun (2017) 76:75–84. doi: 10.1016/j.jaut.2016.09.005
16. Facciotti F, Gagliani N, Häringer B, Alfen JS, Penatti A, Maglie S, et al. IL-10–producing forkhead box protein 3–negative regulatory T cells inhibit b-cell responses and are involved in systemic lupus erythematosus. J Allergy Clin Immunol (2016) 137:318–321.e5. doi: 10.1016/j.jaci.2015.06.044
17. Roncarolo MG, Gregori S, Bacchetta R, Battaglia M, Gagliani N. The biology of T regulatory type 1 cells and their therapeutic application in immune-mediated diseases. Immunity (2018) 49:1004–19. doi: 10.1016/j.immuni.2018.12.001
18. Sayitoglu EC, Freeborn RA, Roncarolo MG. The yin and yang of type 1 regulatory T Cells : From discovery to clinical application. Front Immunol (2021) 12:693105. doi: 10.3389/fimmu.2021.693105
19. Qin S, Cobbold SP, Pope H, Elliott J, Kioussis D, Davies J, et al. “Infectious” transplantation tolerance. Science (1993) 259:974–7. doi: 10.1126/science.8094901
20. Altin JA, Goodnow CC, Cook MC. IL-10 + CTLA-4 + Th2 inhibitory cells form in a Foxp3-independent, IL-2–dependent manner from Th2 effectors during chronic inflammation. J Immunol (2012) 188:5478–88. doi: 10.4049/jimmunol.1102994
21. Cope A, le Friec G, Cardone J, Kemper C. The Th1 life cycle: Molecular control of IFN-γ to IL-10 switching. Trends Immunol (2011) 32:278–86. doi: 10.1016/j.it.2011.03.010
22. Cardone J, le Friec G, Vantourout P, Roberts A, Fuchs A, Jackson I, et al. Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells. Nat Immunol (2010) 11:862–71. doi: 10.1038/ni.1917
23. Ahlers J, Mantei A, Lozza L, Stäber M, Heinrich F, Bacher P, et al. A Notch/STAT3-driven blimp-1/c-Maf-dependent molecular switch induces IL-10 expression in human CD4+ T cells and is defective in crohn´s disease patients. Mucosal Immunol (2022) 15:1–11. doi: 10.1038/s41385-022-00487-x
24. Tsai Y-G, Chien J-W, Chiu Y-M, Su T-C, Chiu P-F, Hsiao K-H, et al. Lupus nephritis with corticosteroid responsiveness: molecular changes of CD46-mediated type 1 regulatory T cells. Pediatr Res (2021). doi: 10.1038/s41390-021-01882-z
25. Gabrysova L, Nicolson KS, Streeter HB, Verhagen J, Sabatos-Peyton CA, Morgan DJ, et al. Negative feedback control of the autoimmune response through antigen-induced differentiation of IL-10-secreting Th1 cells. J Exp Med (2009) 206:1755–67. doi: 10.1084/jem20082118
26. Uyeda MJ, Freeborn RA, Cieniewicz B, Romano R, Chen PP, Liu JM, et al. BHLHE40 regulates IL-10 and IFN-γ production in T cells but does not interfere with human type 1 regulatory T cell differentiation. Front Immunol (2021) 12:683680. doi: 10.3389/fimmu.2021.683680
27. Gagliani N, Magnani CF, Huber S, Gianolini ME, Pala M, Licona-Limon P, et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med (2013) 19:739–46. doi: 10.1038/nm.3179
28. Häringer B, Lozza L, Steckel B, Geginat J. Identification and characterization of IL-10/IFN-γ-producing effector-like T cells with regulatory function in human blood. J Exp Med (2009) 206:1009–17. doi: 10.1084/jem.20082238
29. Okamura T, Fujio K, Shibuya M, Sumitomo S, Shoda H, Sakaguchi S, et al. CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor egr-2. Proc Natl Acad Sci (2009) 106:13974–9. doi: 10.1073/pnas.0906872106
30. Alfen JS, Larghi P, Facciotti F, Gagliani N, Bosotti R, Paroni M, et al. Intestinal IFN-γ–producing type 1 regulatory T cells coexpress CCR5 and programmed cell death protein 1 and downregulate IL-10 in the inflamed guts of patients with inflammatory bowel disease. J Allergy Clin Immunol (2018) 142:1537–1547.e8. doi: 10.1016/j.jaci.2017.12.984
31. Brockmann L, Soukou S, Steglich B, Czarnewski P, Zhao L, Wende S, et al. Molecular and functional heterogeneity of IL-10-producing CD4 + T cells. Nat Commun (2018) 9:5457. doi: 10.1038/s41467-018-07581-4
32. Bauché D, Joyce-Shaikh B, Jain R, Grein J, Ku KS, Blumenschein WM, et al. LAG3 + regulatory T cells restrain interleukin-23-Producing CX3CR1 + gut-resident macrophages during group 3 innate lymphoid cell-driven colitis. Immunity (2018) 49:342–352.e5. doi: 10.1016/j.immuni.2018.07.007
33. Banerjee H, Nieves-rosado H, Kulkarni A, Delgoffe GM, Ferris RL, Kane LP, et al. Expression of Tim-3 drives phenotypic and functional changes in treg cells in secondary lymphoid organs and the tumor microenvironment. CellReports (2021) 36:109699. doi: 10.1016/j.celrep.2021.109699
34. Apetoh L, Quintana FJ, Pot C, Joller N, Xiao S, Kumar D, et al. The aryl hydrocarbon receptor interacts with c-maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol (2010) 11:854–61. doi: 10.1038/ni.1912
35. Zhang H, Madi A, Yosef N, Chihara N, Awasthi A, Pot C, et al. An IL-27-Driven transcriptional network identifies regulators of IL-10 expression across T helper cell subsets. Cell Rep (2020) 33:108433. doi: 10.1016/j.celrep.2020.108433
36. Gandhi R, Kumar D, Burns EJ, Nadeau M, Dake B, Laroni A, et al. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3+ regulatory T cells. Nat Immunol (2010) 11:846–53. doi: 10.1038/ni.1915
37. Tousa S, Semitekolou M, Morianos I, Banos A, Trochoutsou AI, Brodie TM, et al. Activin-a co-opts IRF4 and AhR signaling to induce human regulatory T cells that restrain asthmatic responses. Proc Natl Acad Sci U.S.A. (2017) 114:2891–900. doi: 10.1073/pnas.1616942114
38. Roessner PM, Llaó Cid L, Lupar E, Roider T, Bordas M, Schifflers C, et al. EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia. Leukemia (2021) 35:2311–24. doi: 10.1038/s41375-021-01136-1
39. Bonnal RJP, Rossetti G, Lugli E, de Simone M, Gruarin P, Brummelman J, et al. Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors are associated with disease progression. Nat Immunol (2021) 22:735–45. doi: 10.1038/s41590-021-00930-4
40. Baron U, Floess S, Wieczorek G, Baumann K, Grützkau A, Dong J, et al. DNA Demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3+ conventional T cells. Eur J Immunol (2007) 37:2378–89. doi: 10.1002/eji.200737594
41. Bevington SL, Ng STH, Britton GJ, Keane P, Wraith DC, Cockerill PN. Chromatin priming renders T cell tolerance-associated genes sensitive to activation below the signaling threshold for immune response genes. Cell Rep (2020) 31:107748. doi: 10.1016/j.celrep.2020.107748
42. Yadava K, Medina CO, Ishak H, Gurevich I, Kuipers H, Shamskhou EA, et al. Natural tr1-like cells do not confer long-term tolerogenic memory. Elife (2019) 8:e44821. doi: 10.7554/eLife.44821
43. Omokanye A, Ong LC, Lebrero-Fernandez C, Bernasconi V, Schön K, Strömberg A, et al. Clonotypic analysis of protective influenza M2e-specific lung resident Th17 memory cells reveals extensive functional diversity. Mucosal Immunol (2022) 15:717–29. doi: 10.1038/s41385-022-00497-9
44. Gianfrani C, Levings MK, Sartirana C, Mazzarella G, Barba G, Zanzi D, et al. Gliadin-specific type 1 regulatory T cells from the intestinal mucosa of treated celiac patients inhibit pathogenic T cells. J Immunol (2006) 177:4178–86. doi: 10.4049/jimmunol.177.6.4178
45. Veldman C, Höhne A, Dieckmann D, Schuler G, Hertl M. Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris. J Immunol (2004) 172:6468–75. doi: 10.4049/jimmunol.172.10.6468
46. Li D, Romain G, Flamar AL, Duluc D, Dullaers M, Li XH, et al. Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells. J Exp Med (2012) 209:109–21. doi: 10.1084/jem.20110399
47. Kim JE, Sharma A, Sharma G, Lee SY, Shin HS, Rudra D, et al. Lactobacillus pentosus modulates immune response by inducing IL-10 producing Tr1 cells. Immune Netw (2019) 19:e39. doi: 10.4110/in.2019.19.e39
48. Maquet C, Baiwir J, Loos P, Rodriguez-Rodriguez L, Javaux J, Sandor R, et al. Ly6Chi monocytes balance regulatory and cytotoxic CD4 T cell responses to control virus-induced immunopathology. Sci Immunol (2022) 7:eabn3240. doi: 10.1126/sciimmunol.abn3240
49. Gregori S, Tomasoni D, Pacciani V, Scirpoli M, Battaglia M, Magnani CF, et al. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood (2010) 116:935–44. doi: 10.1182/blood-2011-08-377416
50. Mfarrej B, Jofra T, Morsiani C, Gagliani N, Fousteri G, Battaglia M. Key role of macrophages in tolerance induction via T regulatory type 1 (Tr1) cells. Clin Exp Immunol (2020) 201:222–30. doi: 10.1111/cei.13440
51. Wakkach A, Cottrez F, Groux H. Differentiation of regulatory T cells 1 is induced by CD2 costimulation. J Immunol (2001) 167:3107–13. doi: 10.4049/jimmunol.167.6.3107
52. Sutavani RV, Bradley RG, Ramage JM, Jackson AM, Durrant LG, Spendlove I. CD55 costimulation induces differentiation of a discrete T regulatory type 1 cell population with a stable phenotype. J Immunol (2013) 191:5895–903. doi: 10.4049/jimmunol.1301458
53. Ito T, Yang M, Wang YH, Lande R, Gregorio J, Perng OA, et al. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J Exp Med (2007) 204:105–15. doi: 10.1084/jem.20061660
54. Ding Q, Lu L, Wang B, Zhou Y, Jiang Y, Zhou X, et al. B7H1-ig fusion protein activates the CD4 + IFN-γ receptor + type 1 T regulatory subset through IFN-γ-Secreting Th1 cells. J Immunol (2006) 177:3606–14. doi: 10.4049/jimmunol.177.6.3606
55. Kemper C, Chan AC, Green JM, Brett KA, Murphy KM, Atkinson JP. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature (2003) 421:388–92. doi: 10.1038/nature01315
56. le Friec G, Sheppard D, Whiteman P, Karsten CM, Shamoun SAT, Laing A, et al. The CD46-Jagged1 interaction is critical for human T h 1 immunity. Nat Immunol (2012) 13:1213–21. doi: 10.1038/ni.2454
57. Choileain SN, Hay J, Thomas J, Williams A, Vermeren MM, Benezech C, et al. TCR-stimulated changes in cell surface CD46 expression generate type 1 regulatory T cells. Sci Signal (2017) 10:1–13. doi: 10.1126/scisignal.aah6163
58. Brockmann L, Gagliani N, Steglich B, Giannou AD, Kempski J, Pelczar P, et al. IL-10 receptor signaling is essential for TR1 cell function In vivo. J Immunol (2017) 198:1130–41. doi: 10.4049/jimmunol.1601045
59. Levings MK, Sangregorio R, Galbiati F, Squadrone S, de Waal Malefyt R, Roncarolo M-G. IFN-α and IL-10 induce the differentiation of human type 1 T regulatory cells. J Immunol (2001) 166:5530–9. doi: 10.4049/jimmunol.166.9.5530
60. Zhang P, Lee JS, Gartlan KH, Schuster IS, Comerford I, Varelias A, et al. Eomesodermin promotes the development of type 1 regulatory T (TR1) cells. Sci Immunol (2017) 2:eaah7152. doi: 10.1126/sciimmunol.aah7152
61. Awasthi A, Carrier Y, Peron JPS, Bettelli E, Kamanaka M, Flavell RA, et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol (2007) 8:1380–9. doi: 10.1038/ni1541
62. Pot C, Jin H, Awasthi A, Liu SM, Lai C-Y, Madan R, et al. Cutting edge: IL-27 induces the transcription factor c-maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-Producing Tr1 cells. J Immunol (2009) 183:797–801. doi: 10.4049/jimmunol.0901233
63. Sumida TS, Dulberg S, Schupp JC, Lincoln MR, Stillwell HA, Axisa P, et al. Type I interferon transcriptional network regulates expression of coinhibitory receptors in human T cells. Nat Immunol (2022) 23:632–42. doi: 10.1038/s41590-022-01152-y
64. Bacchetta R, Gregori S, Serafini G, Sartirana C, Schulz U, Zino E, et al. Molecular and functional characterization of allogantigen specific anergic T cells suitable for cell therapy. Haematologica (2010) 95:2134–43. doi: 10.3324/haematol.2010.025825
65. Farez MF, Mascanfroni ID, Méndez-Huergo SP, Yeste A, Murugaiyan G, Garo LP, et al. Melatonin contributes to the seasonality of multiple sclerosis relapses. Cell (2015) 162:1338–52. doi: 10.1016/j.cell.2015.08.025
66. Seki A, Rutz S. Optimized RNP transfection for highly efficient CRISPR / Cas9-mediated gene knockout in primary T cells. J Exp Med (2018) 215:985–97. doi: 10.1084/jem.20171626
67. Shifrut E, Carnevale J, Tobin V, Roth TL, Woo JM, Bui CT, et al. Genome-wide CRISPR screens in primary human T cells reveal key regulators of immune function. Cell (2018) 175:1958–1971.e15. doi: 10.1016/j.cell.2018.10.024
68. Schmidt R, Steinhart Z, Layeghi M, Freimer JW, Nguyen VQ, Blaeschke F, et al. CRISPR activation and interference screens in primary human T cells decode cytokine regulation. Science (2022) 375:eabj4008. doi: 10.1126/science.abj4008
69. Cook L, Stahl M, Han X, Nazli A, MacDonald KN, Wong MQ, et al. Suppressive and gut-reparative functions of human type 1 T regulatory cells. Gastroenterology (2019) 157:1584–98. doi: 10.1053/j.gastro.2019.09.002
70. Liu JM-H, Chen P, Uyeda MJ, Cieniewicz B, Sayitoglu EC, Thomas BC, et al. Pre-clinical development and molecular characterization of an engineered type 1 regulatory T-cell product suitable for immunotherapy. Cytotherapy (2021) 23:10174–1028. doi: 10.1016/j.jcyt.2021.05.010
71. Amodio G, Mugione A, Sanchez AM, Viganò P, Candiani M, Somigliana E, et al. HLA-G expressing DC-10 and CD4+ T cells accumulate in human decidua during pregnancy. Hum Immunol (2013) 74:406–11. doi: 10.1016/j.humimm.2012.11.031
72. Salvany-Celades M, van der Zwan A, Benner M, Setrajcic-Dragos V, Bougleux Gomes HA, Iyer V, et al. Three types of functional regulatory T cells control T cell responses at the human maternal-fetal interface. Cell Rep (2019) 27:2537–47. doi: 10.1016/j.celrep.2019.04.109
73. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell (1993) 75:263–74. doi: 10.1016/0092-8674(93)80068-P
74. Yudoh K, Matsuno H, Nakazawa F, Yonezawa T, Kimura T. Reduced expression of the regulatory CD4+ T cell subset is related to Th1/Th2 balance and disease severity in rheumatoid arthritis. Arthritis Rheum (2000) 43:617–27. doi: 10.1002/1529-0131(200003)43:3<617::AID-ANR19>3.0.CO;2-B
75. Wang L, Wang F-S, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med (2015) 278:369–95. doi: 10.1111/joim.12395
76. Yu H, Gagliani N, Ishigame H, Huber S, Zhu S, Esplugues E, et al. Intestinal type 1 regulatory T cells migrate to periphery to suppress diabetogenic T cells and prevent diabetes development. Proc Natl Acad Sci (2017) 114:10443–8. doi: 10.1073/pnas.1705599114
77. Battaglia M, Stabilini A, Draghici E, Migliavacca B, Gregori S, Bonifacio E, et al. Induction of tolerance in type 1 diabetes via both CD4+CD25+ T regulatory cells and T regulatory type 1 cells. Diabetes (2006) 55:1571–80. doi: 10.2337/db05-1576
78. Chen C, Lee W-H, Yun P, Snow P, Liu C-P. Induction of autoantigen-specific Th2 and Tr1 regulatory T cells and modulation of autoimmune diabetes. J Immunol (2003) 171:733–44. doi: 10.4049/jimmunol.171.2.733
79. Prasad S, Neef T, Xu D, Podojil JR, Getts DR, Shea LD, et al. Tolerogenic Ag-PLG nanoparticles induce tregs to suppress activated diabetogenic CD4 and CD8 T cells. J Autoimmun (2018) 89:112–24. doi: 10.1016/j.jaut.2017.12.010
80. Clemente-Casares X, Blanco J, Ambalavanan P, Yamanouchi J, Singha S, Fandos C, et al. Expanding antigen-specific regulatory networks to treat autoimmunity. Nature (2016) 530:434–40. doi: 10.1038/nature16962
81. Arif S, Tree TI, Astill TP, Tremble JM, Bishop AJ, Dayan CM, et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest (2004) 113:451–63. doi: 10.1172/JCI19585
82. Petrich de Marquesini LG, Fu J, Connor KJ, Bishop AJ, McLintock NE, Pope C, et al. IFN-γ and IL-10 islet-antigen-specific T cell responses in autoantibody-negative first-degree relatives of patients with type 1 diabetes. Diabetologia (2010) 53:1451–60. doi: 10.1007/s00125-010-1739-3
83. Sanda S, Roep BO, von Herrath M. Islet antigen specific IL-10+ immune responses but not CD4+CD25+FoxP3+ cells at diagnosis predict glycemic control in type 1 diabetes. Clin Immunol (2008) 127:138–43. doi: 10.1016/j.clim.2007.12.003
84. Chujo D, Nguyen T-S, Foucat E, Blankenship D, Banchereau J, Nepom GT, et al. Adult-onset type 1 diabetes patients display decreased IGRP-specific Tr1 cells in blood. Clin Immunol (2015) 161:270–7. doi: 10.1016/j.clim.2015.08.014
85. Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M, Bluestone JA. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-ala). J Clin Invest (2003) 111:409–18. doi: 10.1172/JCI16090
86. Alhadj Ali M, Liu Y-F, Arif S, Tatovic D, Shariff H, Gibson VB, et al. Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes. Sci Transl Med (2017) 9:eaaf7779. doi: 10.1126/scitranslmed.aaf7779
87. Barrat FJ, Cua DJ, Boonstra A, Richards DF, Crain C, Savelkoul HF, et al. In vitro generation of interleukin 10–producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)– and Th2-inducing cytokines. J Exp Med (2002) 195:603–16. doi: 10.1084/jem.20011629
88. Mascanfroni ID, Yeste A, Vieira SM, Burns EJ, Patel B, Sloma I, et al. IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat Immunol (2013) 14:1054–63. doi: 10.1038/ni.2695
89. Raverdeau M, Christofi M, Malara A, Wilk MM, Misiak A, Kuffova L, et al. Retinoic acid-induced autoantigen-specific type 1 regulatory T cells suppress autoimmunity. EMBO Rep (2019) 20:e47121. doi: 10.15252/embr.201847121
90. Kenison JE, Jhaveri A, Li Z, Khadse N, Tjon E, Tezza S, et al. Tolerogenic nanoparticles suppress central nervous system inflammation. Proc Natl Acad Sci (2020) 117:32017–28. doi: 10.1073/pnas.2016451117
91. Astier AL, Meiffren G, Freeman S, Hafler DA. Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J Clin Invest (2006) 116:3252–7. doi: 10.1172/JCI29251
92. Caielli S, Veiga DT, Balasubramanian P, Athale S, Domic B, Murat E, et al. A CD4+ T cell population expanded in lupus blood provides b cell help through interleukin-10 and succinate. Nat Med (2019) 25:75–81. doi: 10.1038/s41591-018-0254-9
93. Asnagli H, Martire D, Belmonte N, Quentin J, Bastian H, Boucard-Jourdin M, et al. Type 1 regulatory T cells specific for collagen type II as an efficient cell-based therapy in arthritis. Arthritis Res Ther (2014) 16:R115. doi: 10.1186/ar4567
94. Kim J, Lee J, Gonzalez J, Fuentes-Duculan J, Garcet S, Krueger JG. Proportion of CD4+CD49b+LAG-3+ type 1 regulatory T cells in the blood of psoriasis patients inversely correlates with psoriasis area and severity index. J Invest Dermatol (2018) 138:2669–72. doi: 10.1016/j.jid.2018.05.021
95. Kelly CP, Murray JA, Leffler DA, Getts DR, Bledsoe AC, Smithson G, et al. TAK-101 nanoparticles induce gluten-specific tolerance in celiac disease: A randomized, double-blind, placebo-controlled study. Gastroenterology (2021) 161:66–80.e8. doi: 10.1053/j.gastro.2021.03.014
96. Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med (1999) 190:995–1004. doi: 10.1084/jem.190.7.995
97. Huber S, Gagliani N, Esplugues E, O’Connor W, Huber FJ, Chaudhry A, et al. Th17 cells express interleukin-10 receptor and are controlled by Foxp3– and Foxp3+ regulatory CD4+ T cells in an interleukin-10-Dependent manner. Immunity (2011) 34:554–65. doi: 10.1016/j.immuni.2011.01.020
98. Doñas C, Neira J, Osorio-Barrios F, Carrasco M, Fernández D, Prado C, et al. The demethylase inhibitor GSK-J4 limits inflammatory colitis by promoting de novo synthesis of retinoic acid in dendritic cells. Sci Rep (2021) 11:1342. doi: 10.1038/s41598-020-79122-3
99. Qi L, Wu J, Zhu S, Wang X, Lv X, Liu C, et al. Mesenchymal stem cells alleviate inflammatory bowel disease Via Tr1 cells. Stem Cell Rev Rep (2022) 18:2444–57. doi: 10.1007/s12015-022-10353-9
100. Desreumaux P, Foussat A, Allez M, Beaugerie L, Hébuterne X, Bouhnik Y, et al. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory crohn’s disease. Gastroenterology (2012) 143:1207–1217.e2. doi: 10.1053/j.gastro.2012.07.116
101. Chatenoud L, Ferran C, Bach J-F. The anti-CD3-Induced syndrome: A consequence of massive In vivo cell activation. In: Fleischer B, Sjögren HO (eds) Superantigens. Current Topics in Microbiology and Immunology. (Berlin, Heidelberg: Springer) 174. (1991), 121–34. doi: 10.1007/978-3-642-50998-8_9
102. Jamison BL, Neef T, Goodspeed A, Bradley B, Baker RL, Miller SD, et al. Nanoparticles containing an insulin–ChgA hybrid peptide protect from transfer of autoimmune diabetes by shifting the balance between effector T cells and regulatory T cells. J Immunol (2019) 203:48–57. doi: 10.4049/jimmunol.1900127
103. Getts DR, Martin AJ, McCarthy DP, Terry RL, Hunter ZN, Yap WT, et al. Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat Biotechnol (2012) 30:1217–24. doi: 10.1038/nbt.2434
104. Alatab S, Sepanlou SG, Ikuta K, Vahedi H, Bisignano C, Safiri S, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol (2020) 5:17–30. doi: 10.1016/S2468-1253(19)30333-4
105. Uhlig HH, Coombes J, Mottet C, Izcue A, Thompson C, Fanger A, et al. Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis. J Immunol (2006) 177:5852–60. doi: 10.4049/jimmunol.177.9.5852
106. Kamanaka M, Kim ST, Wan YY, Sutterwala FS, Lara-Tejero M, Galán JE, et al. Expression of interleukin-10 in intestinal lymphocytes detected by an interleukin-10 reporter knockin tiger mouse. Immunity (2006) 25:941–52. doi: 10.1016/j.immuni.2006.09.013
107. Maynard CL, Harrington LE, Janowski KM, Oliver JR, Zindl CL, Rudensky AY, et al. Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3– precursor cells in the absence of interleukin 10. Nat Immunol (2007) 8:931–41. doi: 10.1038/ni1504
108. Himmel ME, Yao Y, Orban PC, Steiner TS, Levings MK. Regulatory T-cell therapy for inflammatory bowel disease: More questions than answers. Immunology (2012) 136:115–22. doi: 10.1111/j.1365-2567.2012.03572.x
109. Asseman C, Read S, Powrie F. Colitogenic Th1 cells are present in the antigen-experienced T cell pool in normal mice: Control by CD4 + regulatory T cells and IL-10. J Immunol (2003) 171:971–8. doi: 10.4049/jimmunol.171.2.971
110. Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity (2008) 28:546–58. doi: 10.1016/j.immuni.2008.02.017
111. Roers A, Siewe L, Strittmatter E, Deckert M, Schlüter D, Stenzel W, et al. T Cell–specific inactivation of the interleukin 10 gene in mice results in enhanced T cell responses but normal innate responses to lipopolysaccharide or skin irritation. J Exp Med (2004) 200:1289–97. doi: 10.1084/jem.20041789
112. Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich J-M, et al. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity (2011) 34:566–78. doi: 10.1016/j.immuni.2011.03.018
113. McGuirk P, McCann C, Mills KHG. Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: A novel strategy for evasion of protective T helper type 1 responses by bordetella pertussis. J Exp Med (2002) 195:221–31. doi: 10.1084/jem.20011288
114. Jofra T, di Fonte R, Galvani G, Kuka M, Iannacone M, Battaglia M, et al. Tr1 cell immunotherapy promotes transplant tolerance via de novo Tr1 cell induction in mice and is safe and effective during acute viral infection. Eur J Immunol (2018) 48:1389–99. doi: 10.1002/eji.201747316
115. Eliasson DG, Omokanye A, Schön K, Wenzel UA, Bernasconi V, Bemark M, et al. M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection. Mucosal Immunol (2018) 11:273–89. doi: 10.1038/mi.2017.14
116. Antunes I, Kassiotis G. Suppression of innate immune pathology by regulatory T cells during influenza a virus infection of immunodeficient mice. J Virol (2010) 84:12564–75. doi: 10.1128/jvi.01559-10
117. Brincks EL, Roberts AD, Cookenham T, Kohlmeier JE, Blackman MA, David L. Antigen-specific memory regulatory CD4 + Foxp3 + T cells control memory responses to influenza virus infection. J Immunol (2013) 190:3438–46. doi: 10.4049/jimmunol.1203140
118. Moser EK, Hufford MM, Braciale TJ. Late engagement of CD86 after influenza virus clearance promotes recovery in a FoxP3 + regulatory T cell dependent manner. PloS Pathog (2014) 10:e1004315. doi: 10.1371/journal.ppat.1004315
119. Rogers MC, Lamens KD, Shafagati N, Johnson M, Oury TD, Joyce S, et al. CD4 + regulatory T cells exert differential functions during early and late stages of the immune response to respiratory viruses. J Immunol (2018) 201:1253–66. doi: 10.4049/jimmunol.1800096
120. Lu C, Zanker D, Lock P, Jiang X, Deng J, Duan M, et al. Memory regulatory T cells home to the lung and control influenza a virus infection. Immunol Cell Biol (2019) 97:774–86. doi: 10.1111/imcb.12271
121. Doetze A, Satoguina J, Burchard G, Rau T, Loliger C, Fleischer B, et al. Antigen-specific cellular hyporesponsiveness in a chronic human helminth infection is mediated by T(h)3/T(r)1-type cytokines IL-10 and transforming growth factor-beta but not by a T(h)1 to T(h)2 shift. Int Immunol (2000) 12:623–30.
122. Koch K, Koch N, Sandaradura De Silva U, Jung N, Schulze Zur Wiesch J, Fatkenheuer G, et al. Increased frequency of CD49b/LAG-3+ type 1 regulatory T cells in HIV-infected individuals. AIDS Res Hum Retroviruses (2015) 31:1238–46. doi: 10.1089/aid.2014.0356
123. Moreira Genaro L, de Oliveira Coser L, da Silva Justo Junior A, Furquim de Castro L, Felício Barreto AK, Rizzato AE, et al. Association between IL-27 and Tr1 cells in severe form of paracoccidioidomycosis. Cytokine (2020) 127:154962. doi: 10.1016/j.cyto.2019.154962
124. MacDonald AJ, Duffy M, Brady MT, McKiernan S, Hall W, Hegarty J, et al. CD4 T helper type 1 and regulatory T cells induced against the same epitopes on the core protein in hepatitis c virus-infected persons. J Infect Dis (2002) 185:720–7. doi: 10.1086/339340
125. Brady MT, MacDonald AJ, Rowan AG, Mills KHG. Hepatitis c virus non-structural protein 4 suppresses Th1 responses by stimulating IL-10 production from monocytes. Eur J Immunol (2003) 33:3448–57. doi: 10.1002/eji.200324251
126. Carpentier A, Conti F, Stenard F, Aoudjehane L, Miroux C, Podevin P, et al. Increased expression of regulatory Tr1 cells in recurrent hepatitis c after liver transplantation. Am J Transplant (2009) 9:2102–12. doi: 10.1111/j.1600-6143.2009.02743.x
127. Fabien S, Olivier M, Khaldoun G, Vivian V, Lynda A, Laurissa O, et al. CD49b, a major marker of regulatory T-cells type 1, predicts the response to antiviral therapy of recurrent hepatitis c after liver transplantation. BioMed Res Int (2014) 2014:290878. doi: 10.1155/2014/290878
128. Utsumi M, Takaki A, Umeda Y, Koike K, Napier SC, Watanabe N, et al. Frequency of regulatory T-cell and hepatitis c viral antigen-specific immune response in recurrent hepatitis c after liver transplantation. Transpl Immunol (2014) 31:33–41. doi: 10.1016/j.trim.2014.05.006
129. Ghazal K, Morales O, Barjon C, Dahlqvist G, Aoudjehane L, Ouaguia L, et al. Early high levels of regulatory T cells and T helper 1 may predict the progression of recurrent hepatitis c after liver transplantation. Clin Res Hepatol Gastroenterol (2019) 43:273–81. doi: 10.1016/j.clinre.2018.10.005
130. Langhorne J, Ndungu FM, Sponaas AM, Marsh K. Immunity to malaria: More questions than answers. Nat Immunol (2008) 9:725–32. doi: 10.1038/ni.f.205
131. Rodriguez-Barraquer I, Arinaitwe E, Jagannathan P, Kamya MR, Rosenthal PJ, Rek J, et al. Quantification of anti-parasite and anti-disease immunity to malaria as a function of age and exposure. Elife (2018) 7:e35832. doi: 10.7554/eLife.35832
132. Jagannathan P, Eccles-James I, Bowen K, Nankya F, Auma A, Wamala S, et al. IFNγ/IL-10 Co-producing cells dominate the CD4 response to malaria in highly exposed children. PloS Pathog (2014) 10:e1003864. doi: 10.1371/journal.ppat.1003864
133. Freitas do Rosário AP, Lamb T, Spence P, Stephens R, Lang A, Roers A, et al. IL-27 promotes IL-10 production by effector Th1 CD4 + T cells: A critical mechanism for protection from severe immunopathology during malaria infection. J Immunol (2012) 188:1178–90. doi: 10.4049/jimmunol.1102755
134. Loevenich K, Ueffing K, Abel S, Hose M, Matuschewski K, Westendorf AM, et al. DC-Derived IL-10 modulates pro-inflammatory cytokine production and promotes induction of CD4+IL-10+ regulatory T cells during plasmodium yoelii infection. Front Immunol (2017) 8:152. doi: 10.3389/fimmu.2017.00152
135. Abel S, Lückheide N, Westendorf AM, Geffers R, Roers A, Müller W, et al. Strong impact of CD4+ Foxp3+ regulatory T cells and limited effect of T cell-derived IL-10 on pathogen clearance during plasmodium yoelii infection. J Immunol (2012) 188:5467–77. doi: 10.4049/jimmunol.1102223
136. Couper KN, Blount DG, Wilson MS, Hafalla JC, Belkaid Y, Kamanaka M, et al. IL-10 from CD4+CD25-Foxp3-CD127 - adaptive regulatory T cells modulates parasite clearance and pathology during malaria infection. PloS Pathog (2008) 4:e1000004. doi: 10.1371/journal.ppat.1000004
137. Lönnberg T, Svensson V, James KR, Fernandez-Ruiz D, Sebina I, Montandon R, et al. Single-cell RNA-seq and computational analysis using temporal mixture modeling resolves TH1/TFH fate bifurcation in malaria. Sci Immunol (2017) 2:eaal2192. doi: 10.1126/sciimmunol.aal2192
138. Soon MSF, Lee HJ, Engel JA, Straube J, Thomas BS, Pernold CPS, et al. Transcriptome dynamics of CD4+ T cells during malaria maps gradual transit from effector to memory. Nat Immunol (2020) 21:1597–610. doi: 10.1038/s41590-020-0800-8
139. Neumann C, Scheffold A, Rutz S. Functions and regulation of T cell-derived interleukin-10. Semin Immunol (2019) 44:101344. doi: 10.1016/j.smim.2019.101344
140. Boyle MJ, Jagannathan P, Bowen K, McIntyre TI, Vance HM, Farrington LA, et al. The development of plasmodium falciparum-specific IL10 CD4 T cells and protection from malaria in children in an area of high malaria transmission. Front Immunol (2017) 8:1329. doi: 10.3389/fimmu.2017.01329
141. Mackroth MS, Abel A, Steeg C, Schulze zur Wiesch J, Jacobs T. Acute malaria induces PD1+CTLA4+ effector T cells with cell-extrinsic suppressor function. PloS Pathog (2016) 12:1–24. doi: 10.1371/journal.ppat.1005909
142. Brandi J, Lehmann C, Kaminski LC, Schulze zur Wiesch J, Addo M, Ramharter M, et al. T Cells expressing multiple co-inhibitory molecules in acute malaria are not exhausted but exert a suppressive function in mice. Eur J Immunol (2022) 52:312–27. doi: 10.1002/eji.202149424
143. Brandi J, Riehn M, Hadjilaou A, Jacobs T. Increased expression of multiple Co-inhibitory molecules on malaria-induced CD8+ T cells are associated with increased function instead of exhaustion. Front Immunol (2022) 13:878320. doi: 10.3389/fimmu.2022.878320
144. Christoffersson G, von Herrath M. Regulatory immune mechanisms beyond regulatory T cells. Trends Immunol (2019) 40:482–91. doi: 10.1016/j.it.2019.04.005
145. Passerini L, di Nunzio S, Gregori S, Gambineri E, Cecconi M, Seidel MG, et al. Functional type 1 regulatory T cells develop regardless of FOXP3 mutations in patients with IPEX syndrome. Eur J Immunol (2011) 41:1120–31. doi: 10.1002/eji.201040909
146. Narula M, Lakshmanan U, Borna S, Schulze JJ, Holmes TH, Harre N, et al. Epigenetic and immunological indicators of IPEX disease in subjects with FOXP3 gene mutation. J Allergy Clin Immunol (2022). doi: 10.1016/j.jaci.2022.09.013
147. Lio CWJ, Hsieh CS. Becoming self-aware: The thymic education of regulatory T cells. Curr Opin Immunol (2011) 23:213–9. doi: 10.1016/j.coi.2010.11.010
148. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med (2004) 199:1567–75. doi: 10.1084/jem.20032058
149. Pacciani V, Gregori S, Chini L, Corrente S, Chianca M, Moschese V, et al. Induction of anergic allergen-specific suppressor T cells using tolerogenic dendritic cells derived from children with allergies to house dust mites. J Allergy Clin Immunol (2010) 125:727–36. doi: 10.1016/j.jaci.2009.12.004
150. Pellerin L, Jenks JA, Chinthrajah S, Dominguez T, Block W, Zhou X, et al. Peanut-specific type 1 regulatory T cells induced in vitro from allergic subjects are functionally impaired. J Allergy Clin Immunol (2018) 141:202–213.e8. doi: 10.1016/j.jaci.2017.05.045
151. Foussat A, Cottrez F, Brun V, Fournier N, Breittmayer J-P, Groux H. A comparative study between T regulatory type 1 and CD4+CD25+ T cells in the control of inflammation. J Immunol (2003) 171:5018–26. doi: 10.4049/jimmunol.171.10.5018
152. Feunou P, Poulin L, Habran C, le Moine A, Goldman M, Braun MY. CD4+ CD25+ and CD4+ CD25– T cells act respectively as inducer and effector T suppressor cells in superantigen-induced tolerance. J Immunol (2003) 171:3475–84. doi: 10.4049/jimmunol.171.7.3475
Keywords: type 1 regulatory T (Tr1) cells, immunological tolerance, autoimmunity, inflammatory bowel disease, infectious disease
Citation: Frontiers Production Office (2023) Erratum: Type 1 regulatory T cell-mediated tolerance in health and disease. Front. Immunol. 13:1125497. doi: 10.3389/fimmu.2022.1125497
Received: 16 December 2022; Accepted: 16 December 2022;
Published: 24 January 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org